FDA Warns Two Chinese API Makers Over Records

The agency sent warning letters and import alerts after two Chinese manufacturers refused or failed to provide requested documents.

Updated on Nov. 11, 2026 in Healthcare

Isometric editorial illustration of plain unmarked shipping containers and stacked drums at a quiet quay, one container door open, in oxblood, teal, and mustard.
The FDA warned Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology on June 17 and 25 after both refused to provide requested records, and issued import alerts covering their drugs. AI Illustration. Upload story photo >

The FDA sent warning letters to Chongqing Qiancan Technology and Tianjin Healthcare Medical Technology for refusing to provide requested records, and issued import alerts covering all drugs and drug products they offer for shipment to the U.S. Both companies supplied active pharmaceutical ingredients intended for compounding.

Why it matters

Import alerts mean imported drugs from these manufacturers can be detained without physical examination until the FDA completes an inspection. The action also signals that stopping U.S. distribution does not erase a manufacturer's obligation to provide records.

The FDA issued import alerts covering all drugs and drug products from two Chinese manufacturers, while a third, Nanjing Hanxin Pharmaceutical Technology, sent requested records and received a separate warning letter. Chongqing Qiancan Technology deregistered on June 29 and reregistered on July 13, and it never provided the records requested.

The players

U.S. Food and Drug Administration

The FDA is the federal agency responsible for regulating drugs, medical devices, and food safety in the United States, including oversight of imported active pharmaceutical ingredients.

The details

The FDA emailed both companies on June 17 requesting records. Tianjin Healthcare Medical Technology replied on June 24 that it would stop producing relevant products for the U.S. market and refused the documents, and the agency repeated its request on June 25 before the company again declined. Chongqing Qiancan Technology never provided its records.

Timeline

  1. June 17: The FDA emailed both companies requesting records.

  2. June 24: Tianjin Healthcare Medical Technology refused the records and said it would stop production.

  3. June 25: The FDA repeated its records request to Tianjin Healthcare Medical Technology.

  4. June 29: Chongqing Qiancan Technology deregistered and discontinued its drug listing.

  5. August 26: The FDA issued import alerts for both companies.

Market Landscape

The FDA's import alert process allows detention of shipments from foreign manufacturers without physical examination until inspection is completed. These actions target the supply of active pharmaceutical ingredients used in compounding, a segment where the agency has increasingly scrutinized overseas suppliers.

Patients whose compounded medications rely on active ingredients from these manufacturers may face shipment detentions and supply disruptions. Pharmacies and compounders sourcing from these suppliers may need to verify alternative ingredient sources.

The takeaway

Regulatory record requests carry real consequences for foreign drug suppliers, even when a company stops selling to the U.S. Buyers of imported ingredients should watch for import alerts as a signal of supply risk.

Further reading

For more on the sector, see Healthcare coverage of drug supply and regulation.